Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company committed to developing and commercializing innovative medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs.

Our focus

We are focusing on the development of treatments for neuromuscular diseases that currently lack treatment options, such as Duchenne muscular dystrophy (DMD).

We have dedicated more than a decade to researching potential treatments in our ongoing mission to make effective medicines available for these often overlooked, life-altering diseases. We are passionate about improving patients’ quality of life and our vision is to be a leader in providing treatments for rare diseases in these areas with high unmet medical needs.

Meet our Board of Directors

Thomas Meier, PhD

Founder, Chairman of the Board and the Scientific Committee, Member of the Compensation and Audit & Compliance Committees

Read more

​Philipp Gutzwiller

Board Member and Chairman of the Audit & Compliance Committee

Read more

Bradley C. Meyer

Board Member and Chairman of the Compensation Committee

Read more

Meet our Executive Committee

Shabir Hasham, MD

Chief Medical Officer

Read more

Marc Schrader

Chief Technology Officer (since 1.1.2024)

Read more

Oliver Strub

General Counsel & Secretary to the Board

Read more

Geert Jan van Daal, MD, PhD

Chief Commercial Officer (since 1.1.2024)

Read more

Meet our Extended Management Team

Ana de Vera, MD

Head of Development, Deputy CMO (since 1.1.2024)

Read more

Sarah Holmes-Klotz

Head of People & Culture

Read more

Eva Kalias

Head Investor Relations & Communications

Read more

Neville Kodkani, MD

Head Global Marketing & Partner Management

Read more

Günther Metz, PhD

Head Business Development

Read more

Sabine Pilot

Head of Clinical Development Operations

Read more